Head to Head Contrast: OPKO Health (NASDAQ:OPK) & Vicarious Surgical (NYSE:RBOT)

Vicarious Surgical (NYSE:RBOT) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Vicarious Surgical and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
OPKO Health	-36.63%	-16.78%	-10.98%

Valuation & Earnings

This table compares Vicarious Surgical and OPKO Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22 million	($6.69)	-0.10
OPKO Health	$581.12 million	1.90	-$225.68 million	($0.27)	-5.41

Vicarious Surgical has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 9.5% of Vicarious Surgical shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Vicarious Surgical and OPKO Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1	2	0	0	1.67
OPKO Health	1	4	0	1	2.17

Vicarious Surgical currently has a consensus target price of $7.00, indicating a potential upside of 907.48%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 6.16%. Given Vicarious Surgical’s higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than OPKO Health.

Risk & Volatility

Vicarious Surgical has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Summary

OPKO Health beats Vicarious Surgical on 8 of the 13 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.